DOCSLIB.ORG

Effect of Early Vasopressin Vs Norepinephrine On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effect of Early Vasopressin Vs Norepinephrine On Protocol Number: CRO1888 VANISH Vasopressin vs Noradrenaline as Initial therapy in Septic Shock PROTOCOL NUMBER: CRO1888 EudraCT NUMBER: 2011-005363-24 SPONSOR: Imperial College London FUNDER: National Institute for Health Research DEVELOPMENT PHASE: PHASE IV STUDY COORDINATION CENTRE: Imperial Clinical Trials Unit PROTOCOL Version & Date: Version 2.1, 02.08.2013 Property of: Dr Anthony Gordon May not be used, divulged or published without the consent of: Dr Anthony Gordon Confidential Final Version2.1, 02.08.2013 Page 1 of 31 Downloaded From: https://jamanetwork.com/ on 09/29/2021 Protocol Number: CRO1888 Study Management Group Chief Investigator: Dr Anthony Gordon Co-investigators: Dr Stephen Brett Prof Gavin Perkins Prof Deborah Ashby Statistician: Dr Alexina Mason Trial Management: Ms Neeraja Thirunavukkarasu Study Coordination Centre For general queries, supply of trial documentation, and collection of data, please contact: Study Coordinator: Ms Neeraja Thirunavukkarasu Address: ICU – 11N, Charing Cross Hospital, Fulham Palace Road London W6 8RF E-mail: [email protected] Clinical Queries Clinical queries should be directed to Ms Neeraja Thirunavukkarasu who will direct the query to the appropriate person Sponsor Imperial College London is the main research Sponsor for this study. For further information regarding the sponsorship conditions, please contact the Head of Regulatory Compliance at: Joint Research Compliance Office 510, Lab block, 5th Floor Charing Cross Hospital Fulham Palace Road London W6 8RF Tel: 0203 311 0213 Fax: 0203 311 0203 Funder National Institute for Health Research – Research for Patient Benefit and Clinician Scientist award schemes This protocol describes the VANISH study and provides information about procedures for entering participants. The protocol should not be used as a guide for the treatment of other participants; every care was taken in its drafting, but corrections or amendments may be necessary. These will be circulated to investigators in the study, but centres entering participants for the first time are advised to contact the trials centre to confirm they have the most recent version. Problems relating to this trial should be referred, in the first instance, to the study coordination centre. This trial will adhere to the principles outlined in the Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031), amended regulations (SI 2006/1928) and the International Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines. It will be conducted in compliance with the protocol, the Data Protection Act and other regulatory requirements as appropriate. Confidential Final Version2.1, 02.08.2013 Page 2 of 31 Downloaded From: https://jamanetwork.com/ on 09/29/2021 Protocol Number: CRO1888 Table of Contents 1 STUDY SUMMARY 6 2 INTRODUCTION 8 2.1 BACKGROUND 8 2.2 RATIONALE FOR CURRENT STUDY 12 3 STUDY OBJECTIVES 12 3.1 PRIMARY OBJECTIVES 12 3.2 SECONDARY OBJECTIVES 13 4 STUDY DESCRIPTION 13 4.1 DESIGN 13 4.2 TREATMENT REGIMEN 13 5 TRIAL METHODS 13 5.1 SUBJECT SELECTION 13 5.1.1 Pre-randomisation evaluations 13 5.1.2 Inclusion Criteria 13 5.1.3 Exclusion Criteria 14 5.2 PROCEDURES AND MEASUREMENTS 14 5.2.1 Screening 14 5.2.2 Informed Consent 14 5.2.3 Randomisation 15 5.2.4 Treatments 16 5.2.5 Follow-Up 18 5.2.6 Lab evaluations 19 5.3 END POINT MANAGEMENT 19 5.3.1 Primary Outcome 19 5.3.2 Secondary Outcome 19 6 PHARMACOVIGILANCE 19 6.1 DEFINITIONS 19 6.2 CAUSALITY 20 6.3 REPORTING PROCEDURES 21 6.4 DATA MONITORING & ETHICAL COMMITTEE 22 7 EARLY DISCONTINUATION OF THE STUDY OR INDIVIDUAL SUBJECTS 23 7.1 EARLY DISCONTINUATION OF THE STUDY 23 7.2 EARLY DISCONTINUATION OF THE SUBJECTS 23 7.3 LOSS TO FOLLOW-UP 23 8 STATISTICS AND DATA ANALYSIS 23 8.1 OUTCOME MEASURES 23 8.2 POWER CALCULATIONS 23 9 TREATMENT 24 9.1 INVESTIGATIONAL MEDICINAL PRODUCT DETAILS 24 9.2 LABELLING, STORAGE AND DISPENSING 24 9.3 ACCOUNTABILITY 24 9.4 UNBLINDING 25 10 REGULATORY, ETHICAL AND LEGAL ISSUES 25 Confidential Final Version2.1, 02.08.2013 Page 3 of 31 Downloaded From: https://jamanetwork.com/ on 09/29/2021 Protocol Number: CRO1888 10.1 DECLARATION OF HELSINKI 25 10.2 GOOD CLINICAL PRACTICE 25 10.3 INDEPENDENT ETHICS COMMITTEE APPROVAL 25 10.3.1 Initial Approval 25 10.3.2 Approval of Amendments 25 10.3.3 Annual Progress Reports and End of Trial Notification 25 10.4 REGULATORY AUTHORITY APPROVAL 25 10.5 TRIAL REGISTRATION 25 10.6 INSURANCE & INDEMNITY 26 10.7 SUBJECT CONFIDENTIALITY 26 10.8 DATA PROTECTION 26 10.9 END OF TRIAL 26 10.10 STUDY DOCUMENTATION AND DATA STORAGE 26 11 ADMINSTRATIVE MATTERS 26 11.1 SOURCE DATA 26 11.2 ELECTRONIC DATA CAPTURE 27 11.3 TRIAL MANAGEMENT 27 11.3.1 Trial Steering Committee 27 11.3.2 Trial Management Group 27 11.3.3 Monitoring 27 11.4 QUALITY CONTROL AND QUALITY ASSURANCE 28 11.5 AUDITS AND INSPECTIONS 28 11.6 PUBLICATION POLICY 28 12 REFERENCES 29 Confidential Final Version2.1, 02.08.2013 Page 4 of 31 Downloaded From: https://jamanetwork.com/ on 09/29/2021 Protocol Number: CRO1888 GLOSSARY OF ABBREVIATIONS ACTH Adrenocorticotrophin Hormone AE Adverse Event AKIN Acute Kidney Injury Network AR Adverse Reaction BMJ British Medical Journal BP Blood Pressure CI Confidence Intervals CRF Case Report Form CTU Clinical Trials Unit DMEC Data Monitoring and Ethics Committee eCRF Electronic Case Record Form EDC Electronic Data Capture GCP Good Clinical Practice GMP Good Manufacturing Practice ICU Intensive Care Unit IMP Investigational Medicinal Product ISF Investigator Site File IV Intravenous MHRA Medicines and Healthcare products Regulatory Agency mRNA Messenger Ribonucleic Acid OR Odds Ratio PerLR Personal Legal Representative PIS Patient Information Sheet ProLR Professional Legal Representative REC Research Ethics Committee RNA Ribonucleic Acid RRT Renal Replacement Therapy SAE Serious Adverse Event ScvO2 Central Venous Oxygen Saturation SIRS Systemic Inflammatory Response Syndrome SmPC Summary of Product Characteristics SOFA Serial Organ Failure Assessment SOP Standard Operating Procedure SUSAR Suspected Unexpected Serious Adverse Reaction TSC Trial Steering Committee TMF Trial Master File TMG Trial Management Group VACS Vasopressin and Corticosteroids in Septic Shock Trial VASST Vasopressin and Septic Shock Trial KEYWORDS Septic shock, vasopressin, noradrenaline, hydrocortisone, blood pressure, acute kidney injury, organ failure Confidential Final Version2.1, 02.08.2013 Page 5 of 31 Downloaded From: https://jamanetwork.com/ on 09/29/2021 Protocol Number: CRO1888 1 STUDY SUMMARY TITLE Vasopressin vs Noradrenaline as Initial therapy in Septic Shock DESIGN Double-blind factorial (2x2) randomised controlled trial AIMS 1. Does vasopressin reduce renal dysfunction compared to noradrenaline when used as the initial vasopressor in the management of adult patients who have septic shock? 2. Is there an interaction between vasopressin and corticosteroids when used in the management of septic shock? POPULATION Adult patients who have septic shock managed in ICU. 412 patients will be recruited for this trial. ELIGIBILITY Adult patient who has sepsis and requires vasopressors to maintain blood pressure despite adequate fluid resuscitation TREATMENT 1. Vasopressin vs. Noradrenaline as initial vasopressor therapy and then 2. Intravenous hydrocortisone vs. “placebo” DURATION Vasopressin vs. Noradrenaline until hypotension has resolved (Maximum 28days) Hydrocortisone vs. “placebo” for 11 days PRIMARY OUTCOME Renal failure free days during the 28 days after randomisation SECONDARY OUTCOMES • Rates and duration of renal replacement therapy • Length of renal failure in survivors and non-survivors • 28-day, ICU and hospital mortality rates. • Organ failure free days in the first 28 days, assessed using the serial organ failure assessment (SOFA) score • Organ support data assessed using the standard NHS Healthcare Resource Groups • Blood, plasma and urinary biomarkers of renal function and inflammation (including genetic polymorphisms). Confidential Final Version2.1, 02.08.2013 Page 6 of 31 Downloaded From: https://jamanetwork.com/ on 09/29/2021 Protocol Number: CRO1888 SCHEMATIC TRIAL PLAN Confidential Final Version2.1, 02.08.2013 Page 7 of 31 Downloaded From: https://jamanetwork.com/ on 09/29/2021 Protocol Number: CRO1888 2 INTRODUCTION 2.1 BACKGROUND Severe sepsis is an increasingly common problem worldwide and is an important cause of mortality (10th most common cause of death in US). In the UK the incidence of severe sepsis has increased 68% over a nine year period, such that in 2004 there were 31,000 patients who had severe sepsis admitted to intensive care units in England, Wales and Northern Ireland.1 A substantial number of patients will also develop severe sepsis after admission to intensive care,2 so the total number of severe sepsis cases may be in excess of 45,000 per annum. As the population ages and receive more complex medical treatments, this will continue to rise. Mortality from sepsis is 35-50%, proportional to illness severity and the number of organs failing. Patients who have sepsis consume a disproportionate amount of resources compared to other critically ill patients. The estimated annual hospital costs for treating these patients in the UK is about £700 million.3 Septic shock, the most severe form of sepsis, is defined as hypotension in response to overwhelming infection.4 As well as appropriate antibiotic treatment one of the main treatments is cardiovascular resuscitation using intravenous fluids and catecholamines. Although usually effective at
Load more

Recommended publications
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Reorganization of Neural Peptidergic Eminence After Hypophysectomy
    The Journal of Neuroscience, October 1994, 14(10): 59966012 Reorganization of Neural Peptidergic Systems Median Eminence after Hypophysectomy Marcel0 J. Villar, Bjiirn Meister, and Tomas Hiikfelt Department of Neuroscience, The Berzelius Laboratory, Karolinska Institutet, Stockholm, 171 77 Sweden Earlier studies have shown the formation of a novel neural crease to a final stage of a few, strongly immunoreactive lobe after hypophysectomy, an experimental manipulation fibers in the external layer at longer survival times. Vaso- that causes transection of neurohypophyseal nerve fibers active intestinal polypeptide (VIP)- and peptide histidine- and removal of pituitary hormones. The mechanisms that isoleucine (PHI)-IR fibers in hypophysectomized animals had underly this regenerative process are poorly understood. already contacted portal vessels 5 d after hypophysectomy, The localization and number of peptide-immunoreactive and from then on progressively increased in numbers. Fi- (-IR) fibers in the median eminence were studied in normal nally, most of the peptide fibers described above formed rats and in rats at different times of survival after hypophy- dense innervation patterns around the large blood vessels sectomy using indirect immunofluorescence histochemistry. along the lateral borders of the median eminence. The number of vasopressin (VP)-IR fibers increased in the The present results show that hypophysectomy induces external layer of the median eminence in 5 d hypophysec- a wide variety of changes in hypothalamic neurosecretory tomized rats. Oxytocin (OXY)-IR fibers decreased in the in- fibers. Not only is the expression of several peptides in these ternal layer and progressively extended into the external fibers modified following different survival times, but a re- layer.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Vaginal Administration of Contraceptives
    Scientia Pharmaceutica Review Vaginal Administration of Contraceptives Esmat Jalalvandi 1,*, Hafez Jafari 2 , Christiani A. Amorim 3 , Denise Freitas Siqueira Petri 4 , Lei Nie 5,* and Amin Shavandi 2,* 1 School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK 2 BioMatter Unit, École Polytechnique de Bruxelles, Université Libre de Bruxelles, Avenue F.D. Roosevelt, 50-CP 165/61, 1050 Brussels, Belgium; [email protected] 3 Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium; [email protected] 4 Fundamental Chemistry Department, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, São Paulo 05508-000, Brazil; [email protected] 5 College of Life Sciences, Xinyang Normal University, Xinyang 464000, China * Correspondence: [email protected] (E.J.); [email protected] (L.N.); [email protected] (A.S.); Tel.: +32-2-650-3681 (A.S.) Abstract: While contraceptive drugs have enabled many people to decide when they want to have a baby, more than 100 million unintended pregnancies each year in the world may indicate the contraceptive requirement of many people has not been well addressed yet. The vagina is a well- established and practical route for the delivery of various pharmacological molecules, including contraceptives. This review aims to present an overview of different contraceptive methods focusing on the vaginal route of delivery for contraceptives, including current developments, discussing the potentials and limitations of the modern methods, designs, and how well each method performs for delivering the contraceptives and preventing pregnancy.
    [Show full text]
  • Vasopressin Versus Norepinephrine in Septic Shock: a Propensity Score Matched Efficiency Retrospective Cohort Study in the VASST Coordinating Center Hospital James A
    Russell et al. Journal of Intensive Care (2018) 6:73 https://doi.org/10.1186/s40560-018-0344-2 RESEARCH Open Access Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital James A. Russell1,2*, Hugh Wellman3 and Keith R. Walley1,2 Abstract Purpose: It is not clear whether vasopressin versus norepinephrine changed mortality in clinical practice in the Vasopressin and Septic Shock Trial (VASST) coordinating center hospital after VASST was published. We tested the hypothesis that vasopressin changed mortality compared to norepinephrine using propensity matching of vasopressin to norepinephrine-treated patients in the VASST coordinating center hospital before (SPH1) and after (SPH2) VASST was published. Methods: Vasopressin-treated patients were propensity score matched to norepinephrine-treated patients based on age, APACHE II, respiratory, renal, and hematologic dysfunction, mechanical ventilation status, medical/surgical status, infection site, and norepinephrine dose. The propensity score estimated the probability that a patient would have received vasopressin given baseline characteristics. For sensitivity analysis, we then excluded patients who had underlying severe congestive heart failure. The primary outcome was 28-day mortality. Results: Vasopressin- and norepinephrine-treated patients were similar after matching in SPH1 (pre-VASST); vasopressin-treated patients (n = 158) had a significantly higher mortality than norepinephrine-treated patients (n = 158) (60.8 vs. 46.2%, p = 0.009). In SPH2 after matching, the 28-day mortality rates were not significantly different; 31.2% and 26.9% in the vasopressin (n = 93) and norepinephrine (n = 93) groups, respectively (p = 0.518). The day 1 vasopressin dose in SPH1 vs.
    [Show full text]
  • Responses Induced by Arginine-Vasopressin Injection in the Plasma Concentrations of Adrenocorticotropic Hormone, Cortisol, Growt
    249 Responses induced by arginine-vasopressin injection in the plasma concentrations of adrenocorticotropic hormone, cortisol, growth hormone and metabolites around weaning time in goats K Katoh, M Yoshida, Y Kobayashi, M Onodera, K Kogusa and Y Obara Department of Animal Physiology, Graduate School of Agricultural Science, Tohoku University, Tsutsumidori, Aoba-ku, Sendai 981-8555, Japan (Requests for offprints should be addressed to Y Obara; Email: [email protected]) Abstract In order to assess the biological significance of weaning responses induced by stimulation with AVP were weaker and water deprivation on the control of plasma con- than those induced in 13-week-old goats. Additionally, centrations of adrenocorticotropic hormone (ACTH), cor- there were no responses in any hormone patterns to CRH tisol, growth hormone (GH) and metabolites in response stimulation in 4-week-old goats. In experiment 3, 13- to stimulation with arginine-vasopressin (AVP) and week-old goats were injected with CRH alone followed corticotropin-releasing hormone (CRH), we carried out by injection with AVP for two consecutive days of water three experiments in which male goats before and after deprivation. The animals were subjected to withdrawal of weaning were intravenously injected with AVP or CRH up to 20% of the total blood volume and water deprivation alone, or in combination with each other. In experiment 1, for up to 28 h. However, no significant differences in 17-week-old (post-weaning) goats were intravenously plasma ACTH, cortisol or GH levels were observed injected with AVP or CRH alone at the doses of 0·1, 0·3 between days 1 and 2.
    [Show full text]
  • Preferred Drug List
    Kansas State Employee ANALGESICS Second Generation cefprozil Health Plan NSAIDs cefuroxime axetil diclofenac sodium delayed-rel Preferred Drug List diflunisal Third Generation etodolac cefdinir 2021 ibuprofen cefixime (SUPRAX) meloxicam nabumetone Erythromycins/Macrolides naproxen sodium tabs azithromycin naproxen tabs clarithromycin oxaprozin clarithromycin ext-rel sulindac erythromycin delayed-rel erythromycin ethylsuccinate NSAIDs, COMBINATIONS erythromycin stearate diclofenac sodium delayed-rel/misoprostol fidaxomicin (DIFICID) Effective 04/01/2021 NSAIDs, TOPICAL Fluoroquinolones diclofenac sodium gel 1% ciprofloxacin For questions or additional information, diclofenac sodium soln levofloxacin access the State of Kansas website at moxifloxacin http://www.kdheks.gov/hcf/sehp or call COX-2 INHIBITORS Penicillins the Kansas State Employees Prescription celecoxib amoxicillin Drug Program at 1-800-294-6324. amoxicillin/clavulanate The Preferred Drug List is subject to change. GOUT amoxicillin/clavulanate ext-rel To locate covered prescriptions online, allopurinol ampicillin access the State of Kansas website at colchicine tabs dicloxacillin http://www.kdheks.gov/hcf/sehp for the probenecid penicillin VK most current drug list. colchicine (MITIGARE) Tetracyclines What is a Preferred Drug List? OPIOID ANALGESICS doxycycline hyclate A Preferred Drug List is a list of safe and buprenorphine transdermal minocycline cost-effective drugs, chosen by a committee codeine/acetaminophen tetracycline of physicians and pharmacists. Drug lists fentanyl
    [Show full text]
  • The Effect of Triamcinolone Acetonide on Collagen Synthesis
    THE EFFECT OF TRIAMCINOLONE ACETONIDE ON COLLAGEN SYNTHESIS BY HUMAN AND MOUSE DERMAL FIBROBLASTS IN CELL CULTURE by ELAINE MEI LI|TAN B. Sc., The University of British Columbia, 1976 A THESIS SUBMITTED IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE in THE FACULTY OF GRADUATE STUDIES (Division of Pharmaceutics and Biopharmaceutics) We accept this thesis as conforming to the required standard THE UNIVERSITY OF BRITISH COLUMBIA JANUARY 1980 (?) Elaine Mei Li Jan, 1980 ii In presenting this thesis in partial fulfilment of the requirements fo an advanced degree at the University of British Columbia, I agree that the Library shall make it freely available for reference and study. I further agree that permission for extensive copying of this thesis for scholarly purposes may be granted by the Head of my Department or by his representatives. It is understood that copying or publication of this thesis for financial gain shall not be allowed without my written permission. Department of The University of British Columbia 2075 Wesbrook Place Vancouver, Canada V6T 1WS Date SO, tffd - iii - ABSTRACT Glucocorticoids are known to affect metabolic activities of cells. The mechanism of glucocorticoid actions in adult human dermal and mouse L-929 fibroblasts have yet to be fully ascertained. This study endeavors to examine the effects of one glucocorticoid, triamcinolone acetonide, on cellular proliferation and collagen synthesis and to compare such effects in the human and mouse cell lines. Cellular proliferation and collagen synthesis are analyzed and quantitated by cell counts and selective digestion of the protein by bacterial collagenase, respectively.
    [Show full text]
  • GIP-Dependent Expression of Hypothalamic Genes
    GIP-dependent expression of hypothalamic genes Suresh Ambati1, Jiuhua Duan1a, Diane L. Hartzell1, Yang-Ho Choi3, Mary Anne Della- Fera1 and Clifton A. Baile1,2 1Department of Animal and Dairy Science, 2Department of Foods and Nutrition, University of Georgia, Athens GA 30602, USA. 3Department of Animal Science and Institute of Agriculture & Life Sciences, Gyeongsang National University, Jinju 660-701, Korea Correspondence: Dr. Clifton A. Baile, 444 Rhodes Center, University of Georgia, Athens GA 30602-2771. Tel: (706) 542-4094; Fax: (706) 542-7925; e-mail: [email protected] Short Title: GIP-dependent expression of hypothalamic genes a Current address: Dept. of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada M5S 1A1 1 SUMMARY GIP (glucose dependent insulinotrophic polypeptide), originally identified as an incretin peptide synthesized in the gut, has recently been identified, along with its receptors (GIPR), in the brain. Our objective was to investigate the role of GIP in hypothalamic gene expression of biomarkers linked to regulating energy balance and feeding behavior related neurocircuitry. Rats with lateral cerebroventricular cannulas were administered 10 g GIP or 10 l artificial cerebrospinal fluid (aCSF) daily for 4 days, after which whole hypothalami were collected. Real time Taqman™ RT-PCR was used to quantitatively compare the mRNA expression levels of a set of genes in the hypothalamus. Administration of GIP resulted in up-regulation of hypothalamic mRNA levels of AVP (46.9+4.5%), CART (25.9+2.7%), CREB1 (38.5+4.5%), GABRD (67.1+11%), JAK2 (22.1+3.6%), MAPK1 (33.8+7.8%), NPY (25.3 5.3%), OXT (49.1+5.1%), STAT3 (21.6+3.8%), and TH (33.9+8.5%).
    [Show full text]
  • Pharmaceutical Compoundingand Dispensing, Second
    Pharmaceutical Compounding and Dispensing Pharmaceutical Compounding and Dispensing SECOND EDITION John F Marriott BSc, PhD, MRPharmS, FHEA Professor of Clinical Pharmacy Aston University School of Pharmacy, UK Keith A Wilson BSc, PhD, FRPharmS Head of School Aston University School of Pharmacy, UK Christopher A Langley BSc, PhD, MRPharmS, MRSC, FHEA Senior Lecturer in Pharmacy Practice Aston University School of Pharmacy, UK Dawn Belcher BPharm, MRPharmS, FHEA Teaching Fellow, Pharmacy Practice Aston University School of Pharmacy, UK Published by the Pharmaceutical Press 1 Lambeth High Street, London SE1 7JN, UK 1559 St Paul Avenue, Gurnee, IL 60031, USA Ó Pharmaceutical Press 2010 is a trade mark of Pharmaceutical Press Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society of Great Britain First edition published 2006 Second edition published 2010 Typeset by Thomson Digital, Noida, India Printed in Great Britain by TJ International, Padstow, Cornwall ISBN 978 0 85369 912 5 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The right of John F Marriott, Keith A Wilson, Christopher A Langley and Dawn Belcher to be identified as the author of this work has been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]